AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 221 filers reported holding AMICUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,781,231 | -14.3% | 557,667 | -11.4% | 0.01% | 0.0% |
| Q2 2023 | $7,909,835 | -11.0% | 629,764 | -21.4% | 0.01% | -28.6% |
| Q1 2023 | $8,883,567 | +35.6% | 801,043 | +49.3% | 0.01% | +16.7% |
| Q4 2022 | $6,549,676 | -10.4% | 536,419 | -23.3% | 0.01% | +20.0% |
| Q3 2022 | $7,306,000 | +1.9% | 699,744 | +4.8% | 0.01% | 0.0% |
| Q2 2022 | $7,172,000 | +226.9% | 667,698 | +188.1% | 0.01% | +400.0% |
| Q1 2022 | $2,194,000 | -62.7% | 231,763 | -54.5% | 0.00% | -66.7% |
| Q4 2021 | $5,883,000 | +96.3% | 509,286 | +62.3% | 0.00% | +50.0% |
| Q3 2021 | $2,997,000 | -38.5% | 313,881 | -37.9% | 0.00% | -33.3% |
| Q2 2021 | $4,876,000 | +14.1% | 505,805 | +16.9% | 0.00% | 0.0% |
| Q1 2021 | $4,275,000 | +36.6% | 432,795 | +219.4% | 0.00% | +200.0% |
| Q4 2020 | $3,129,000 | +264.3% | 135,523 | +122.8% | 0.00% | – |
| Q3 2020 | $859,000 | -76.8% | 60,822 | -75.2% | 0.00% | -100.0% |
| Q2 2020 | $3,702,000 | +48.7% | 245,457 | -8.9% | 0.00% | 0.0% |
| Q1 2020 | $2,489,000 | +64.4% | 269,498 | +73.3% | 0.00% | +100.0% |
| Q4 2019 | $1,514,000 | -12.1% | 155,476 | -27.6% | 0.00% | 0.0% |
| Q3 2019 | $1,722,000 | -43.1% | 214,767 | -11.4% | 0.00% | -50.0% |
| Q2 2019 | $3,024,000 | +519.7% | 242,308 | +577.0% | 0.00% | – |
| Q1 2019 | $488,000 | -93.7% | 35,792 | -95.5% | 0.00% | -100.0% |
| Q4 2018 | $7,697,000 | -63.2% | 803,388 | -53.5% | 0.01% | -61.1% |
| Q3 2018 | $20,901,000 | +163.3% | 1,728,703 | +240.2% | 0.02% | +125.0% |
| Q2 2018 | $7,937,000 | +287.4% | 508,117 | +272.8% | 0.01% | +700.0% |
| Q1 2018 | $2,049,000 | +13.3% | 136,303 | +8.4% | 0.00% | 0.0% |
| Q4 2017 | $1,809,000 | -26.5% | 125,718 | -22.9% | 0.00% | -66.7% |
| Q3 2017 | $2,460,000 | -17.1% | 163,067 | -44.7% | 0.00% | 0.0% |
| Q2 2017 | $2,966,000 | +74.4% | 294,652 | +23.5% | 0.00% | +200.0% |
| Q1 2017 | $1,701,000 | -14.4% | 238,550 | -40.3% | 0.00% | 0.0% |
| Q4 2016 | $1,986,000 | +359.7% | 399,490 | +583.8% | 0.00% | – |
| Q3 2016 | $432,000 | +158.7% | 58,418 | +91.3% | 0.00% | – |
| Q2 2016 | $167,000 | -85.0% | 30,532 | -76.9% | 0.00% | -100.0% |
| Q1 2016 | $1,116,000 | +77.7% | 132,041 | +104.1% | 0.00% | – |
| Q4 2015 | $628,000 | -94.8% | 64,701 | -92.6% | 0.00% | -100.0% |
| Q3 2015 | $12,167,000 | +8233.6% | 869,781 | +8301.2% | 0.01% | – |
| Q2 2015 | $146,000 | -2.7% | 10,353 | -24.8% | 0.00% | – |
| Q1 2015 | $150,000 | -19.4% | 13,773 | -38.5% | 0.00% | – |
| Q4 2014 | $186,000 | +18500.0% | 22,394 | +24241.3% | 0.00% | – |
| Q3 2014 | $1,000 | -91.7% | 92 | -98.4% | 0.00% | – |
| Q1 2014 | $12,000 | -63.6% | 5,771 | -59.6% | 0.00% | – |
| Q4 2013 | $33,000 | -45.9% | 14,274 | -45.8% | 0.00% | – |
| Q3 2013 | $61,000 | – | 26,338 | +11013.1% | 0.00% | – |
| Q2 2013 | $0 | – | 237 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |